Subgroup analyses
We performed several subgroup analyses as mentioned below. When
restricted the research center to non-European country, we found that
CRT-D showed a trend of mortality benefits in all-cause mortality, which
did not reach the statistically significant (HR: 0.90, 95%CI:
0.80-1.01, I2=0%, P=0.085) (Supplementary Figure 3).
For CRT-D in primary prevention, the pooled HR suggested that additional
ICD therapy did not reduce all-cause mortality (HR: 0.92, 95%CI:
0.74-1.14, I2=0%, P=0.444) (Supplementary Figure 4).
With long-term follow-up (≥5 years), CRT-D also did not show advantages
in reducing all-cause mortality compared to CRT-P (HR: 0.78, 95%CI:
0.46-1.34, I2=76.4%, P=0.373) (Supplementary Figure
5).